Furthermore, leveraging the canonical SMILES structure of NGR1 obtained from PubChem, we predicted its potential drug targets (Fig. 1D) and subsequently identified potential drug targets associated with glomerular injury in DN patients, such as VEGFA, FGF1, ITGB5, LGALS8, SLC5A2, and BACE1. This evidence concerns the gene SLC5A2 and liver dysplastic nodule.